BACKGROUND: The association of glucose variability (GV) with other glycemic measures is emerging as a topic of interest. The aim of this analysis is to study the correlation between GV and measures of glycemic control, such as glycated hemoglobin (HbA1c) and daily mean glucose (DMG). METHODS: Data from 5 phase 3 trials were pooled into 3 analysis groups: type 2 diabetes (T2D) treated with basal insulin only, T2D treated with basal-bolus therapy, and type 1 diabetes (T1D). A generalized boosted model was used post hoc to assess the relationship of the following variables with glycemic control parameters (HbA1c and DMG): within-day GV, between-day GV (calculated using self-monitored blood glucose and fasting blood glucose [FBG]), hypoglycemia rate, and certain baseline characteristics. RESULTS: Within-day GV (calculated using standard deviation [SD]) was found to have a significant influence on endpoints HbA1c and DMG in all 3 patient groups. Between-day GV from FBG (calculated using SD), within-day GV (calculated using coefficient of variation), and hypoglycemia rate were found to significantly influence the endpoint HbA1c in the T2D basal-only group. CONCLUSIONS: Lower within-day GV was significantly associated with improvement in DMG and HbA1c. This finding suggests that GV could be a marker in the early phases of new antihyperglycemic therapy development for predicting clinical outcomes in terms of HbA1c and DMG.
BACKGROUND: The association of glucose variability (GV) with other glycemic measures is emerging as a topic of interest. The aim of this analysis is to study the correlation between GV and measures of glycemic control, such as glycated hemoglobin (HbA1c) and daily mean glucose (DMG). METHODS: Data from 5 phase 3 trials were pooled into 3 analysis groups: type 2 diabetes (T2D) treated with basal insulin only, T2D treated with basal-bolus therapy, and type 1 diabetes (T1D). A generalized boosted model was used post hoc to assess the relationship of the following variables with glycemic control parameters (HbA1c and DMG): within-day GV, between-day GV (calculated using self-monitored blood glucose and fasting blood glucose [FBG]), hypoglycemia rate, and certain baseline characteristics. RESULTS: Within-day GV (calculated using standard deviation [SD]) was found to have a significant influence on endpoints HbA1c and DMG in all 3 patient groups. Between-day GV from FBG (calculated using SD), within-day GV (calculated using coefficient of variation), and hypoglycemia rate were found to significantly influence the endpoint HbA1c in the T2D basal-only group. CONCLUSIONS: Lower within-day GV was significantly associated with improvement in DMG and HbA1c. This finding suggests that GV could be a marker in the early phases of new antihyperglycemic therapy development for predicting clinical outcomes in terms of HbA1c and DMG.
Entities:
Keywords:
daily mean glucose; glucose variability; glycated hemoglobin; glycemic control
Authors: Simona Frontoni; Paolo Di Bartolo; Angelo Avogaro; Emanuele Bosi; Giuseppe Paolisso; Antonio Ceriello Journal: Diabetes Res Clin Pract Date: 2013-09-25 Impact factor: 5.602
Authors: Simon Heller; John Buse; Miles Fisher; Satish Garg; Michel Marre; Ludwig Merker; Eric Renard; David Russell-Jones; Areti Philotheou; Ann Marie Ocampo Francisco; Huiling Pei; Bruce Bode Journal: Lancet Date: 2012-04-21 Impact factor: 79.321
Authors: Alan J Garber; Allen B King; Stefano Del Prato; Seamus Sreenan; Mustafa K Balci; Manuel Muñoz-Torres; Julio Rosenstock; Lars A Endahl; Ann Marie Ocampo Francisco; Priscilla Hollander Journal: Lancet Date: 2012-04-21 Impact factor: 79.321
Authors: R M Bergenstal; H Lunt; E Franek; F Travert; J Mou; Y Qu; C J Antalis; M L Hartman; M Rosilio; S J Jacober; E J Bastyr Journal: Diabetes Obes Metab Date: 2016-08-03 Impact factor: 6.577